BofA analyst Jason Gerberry raised the firm’s price target on Teva (TEVA) to $22 from $20 and keeps a Buy rating on the shares following what the firm views as “a solid 1Q update,” mainly driven by cost saving initiatives. Factoring in cost savings, the firm is more confident in Teva’s ability to grow its bottom-line in 2026 despite major product headwind and approach its 2027 profitability targets, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva Pharmaceuticals: Positioned for Growth with Strategic Cost-Saving Initiatives and New Product Cycle
- Teva Reports Strong Q1 2025 Growth with Innovative Medicines
- Teva Pharmaceuticals’ Earnings Call: Growth and Strategic Focus
- Teva reports Q1 EPS 52c, consensus 46c
- Teva sees FY25 EPS $2.45-$2.65, consensus $2.56